Treatment of chronic idiopathic systemic vasculitides.
The following review is intended to summarize currently accepted, as well as newly appreciated therapies for the chronic systemic vasculitides. In recent years, a great deal has been learned about enhancement and inhibition of immunoinflammatory phenomena. Biological, immunomodulatory agents with focussed actions are just beginning to be tested in the clinical setting. However, until these promising approaches have been more thoroughly evaluated, it will continue to be necessary to cautiously titrate broadly immunosuppressive medications for the treatment of these disorders.
Hoffman
G S
GS
Vasculitis and Related Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
D005938:Glucocorticoids / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000628:therapy; D006801:Humans; D010488:Polyarteritis Nodosa / Q000628:therapy; D013625:Takayasu Arteritis / Q000628:therapy; D014657:Vasculitis / Q000628:therapy*
D005938:Glucocorticoids